Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaTony Mok, Masahiro Fukuoka, Yukito Ichinose et al.|New England Journal of Medicine|2009Cited by 8.2k
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Nick Thatcher, Kevin Carroll, Alex Y. Chang et al.|The Lancet|2005Cited by 2.1k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)Masahiro Fukuoka, Tony Mok, Yi‐Long Wu et al.|Journal of Clinical Oncology|2011Cited by 1.6k
Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and ChemotherapyTony Mok, Lin Wu, Yi‐Long Wu et al.|Clinical Cancer Research|2015Cited by 469